Loading...
•
Jun 30, 2024
Journey Medical Q2 2024 Earnings Report
Reported a revenue increase and positive Adjusted EBITDA.
Key Takeaways
Journey Medical reported a 14% sequential increase in total net product revenue, reaching $14.9 million, and positive Adjusted EBITDA for the second quarter of 2024. The company is focused on its core dermatology franchise and the upcoming launch of DFD-29.
Total revenues for Q2 2024 were $14.9 million, a 14% increase from Q1 2024.
The company delivered positive Adjusted EBITDA.
Journey Medical is preparing for the DFD-29 PDUFA date.
Joseph M. Benesch was appointed as permanent Chief Financial Officer and Michael C. Pearce joined the Board of Directors.
Forward Guidance
Journey Medical anticipates a productive second half of 2024 with additional business progress and continued financial performance.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...